Cannabinoids and the skeleton: From marijuana to reversal of bone loss

References

• Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4: 873–84
   PubMed Web of Science ®Google Scholar
• Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005; 48: 5059–87
   PubMed Web of Science ®Google Scholar
• Hohmann AG, Suplita RL 2nd. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006; 8: E693–708
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006; 147(Suppl 1)S163–71
   PubMed Web of Science ®Google Scholar
• Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007; 9: 413–30
   PubMedGoogle Scholar
• Marx J. Drug development. Drugs inspired by a drug. Science. 2006; 311: 322–5
   PubMed Web of Science ®Google Scholar
• Yazulla S. Endocannabinoids in the retina: From marijuana to neuroprotection. Prog Retin Eye Res. 2008; 27: 501–26
   PubMed Web of Science ®Google Scholar
• Iversen L. The science of marijuana. Oxford University Press, New York 2000
   Google Scholar
• Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot Essent Fatty Acids. 2002; 66: 93–9
   PubMed Web of Science ®Google Scholar
• Iversen L. Cannabis and the brain. Brain. 2003; 126: 1252–70
   PubMed Web of Science ®Google Scholar
• Akbas F, Gasteyger C, Sjodin A, Astrup A, Larsen TM. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev. 2009; 10: 58–67
   PubMed Web of Science ®Google Scholar
• Bab I. The skeleton: stone bones and stoned heads?. Cannabinoids as therapeutics. Milestones in drug therapy series, R Mechoulam. Birkhäuser Verlag, Basel 2005; 201–6
   Google Scholar
• Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005; 11: 774–9
   PubMed Web of Science ®Google Scholar
• Bab I, Hajbi-Yonissi C, Gabet Y, Müller R. Micro-tomographic atlas of the mouse skeleton. Springer, New York 2007; 195–9
   Google Scholar
• Parfitt AM. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res. 1982; 4: 1–6
   PubMedGoogle Scholar
• Roodman GD. Cell biology of the osteoclast. Exp Hematol. 1999; 27: 1229–41
   PubMed Web of Science ®Google Scholar
• Bab I, Ashton BA, Gazit D, Marx G, Williamson MC, Owen ME. Kinetics and differentiation of marrow stromal cells in diffusion chambers in vivo. J Cell Sci. 1986; 84: 139–51
   PubMed Web of Science ®Google Scholar
• Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21: 115–37
   PubMed Web of Science ®Google Scholar
• Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994; 13: 1189–96
   PubMed Web of Science ®Google Scholar
• Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp. 2001; 232: 235–47
   PubMedGoogle Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89: 309–19
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165–76
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12: 1260–8
   PubMed Web of Science ®Google Scholar
• Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397: 315–23
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, et al. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell. 2000; 103: 1085–97
   PubMed Web of Science ®Google Scholar
• Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord. 2006; 7: 33–9
   PubMed Web of Science ®Google Scholar
• Most W, van der Wee-Pals L, Ederveen A, Papapoulos S, Lowik C. Ovariectomy and orchidectomy induce a transient increase in the osteoclastogenic potential of bone marrow cells in the mouse. Bone. 1997; 20: 27–30
   PubMedGoogle Scholar
• Gabet Y, Kohavi D, Muller R, Chorev M, Bab I. Intermittently administered parathyroid hormone 1–34 reverses bone loss and structural impairment in orchiectomized adult rats. Osteoporos Int. 2005; 16: 1436–43
   PubMedGoogle Scholar
• Alexander JM, Bab I, Fish S, Müller R, Uchiyama T, Gronowicz G, et al. Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. J Bone Miner Res. 2001; 16: 1665–73
   PubMed Web of Science ®Google Scholar
• Potts JT, Juppner H. Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism, and bone development: the proteins, their genes, and receptors. Academic Press, San Diego 1998
   Google Scholar
• Gunther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature. 2000; 406: 199–203
   PubMed Web of Science ®Google Scholar
• Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest. 1986; 78: 355–60
   PubMed Web of Science ®Google Scholar
• Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002; 110: 771–81
   PubMed Web of Science ®Google Scholar
• Bab I, Chorev M. Osteogenic growth peptide: from concept to drug design. Biopolymers. 2002; 66: 33–48
   PubMedGoogle Scholar
• Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135: 825–37
   PubMed Web of Science ®Google Scholar
• Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000; 100: 197–207
   PubMed Web of Science ®Google Scholar
• Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002; 109: 915–21
   PubMed Web of Science ®Google Scholar
• Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002; 111: 305–17
   PubMed Web of Science ®Google Scholar
• Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003; 115: 151–62
   PubMed Web of Science ®Google Scholar
• Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, et al. FSH directly regulates bone mass. Cell. 2006; 125: 247–60
   PubMed Web of Science ®Google Scholar
• Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002; 68–69: 619–31
   PubMed Web of Science ®Google Scholar
• Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005; 128: 742–55
   PubMed Web of Science ®Google Scholar
• Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005; 434: 782–6
   PubMed Web of Science ®Google Scholar
• Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, et al. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci. 1999; 65: 627–35
   PubMedGoogle Scholar
• Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A. 1999; 96: 14228–33
   PubMed Web of Science ®Google Scholar
• Howlett, AC. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005; 53–79
   PubMedGoogle Scholar
• Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008; 105: 2699–704
   PubMed Web of Science ®Google Scholar
• Pertwee RG. GPR55: a new member of the cannabinoid receptor clan?. Br J Pharmacol. 2007; 152: 984–6
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem. 2001; 276: 12856–63
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258: 1946–9
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995; 50: 83–90
   PubMed Web of Science ®Google Scholar
• Hansen HS, Moesgaard B, Hansen HH, Petersen G. N-Acylethanolamines and precursor phospholipids—relation to cell injury. Chem Phys Lipids. 2000; 108: 135–50
   PubMedGoogle Scholar
• Willoughby KA, Moore SF, Martin BR, Ellis EF. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther. 1997; 282: 243–7
   PubMed Web of Science ®Google Scholar
• Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem. 2006; 281: 26465–72
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98: 9371–6
   PubMed Web of Science ®Google Scholar
• Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 1998; 12: 1035–44
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem. 1999; 264: 258–67
   PubMedGoogle Scholar
• Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997; 388: 773–8
   PubMed Web of Science ®Google Scholar
• Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003; 163: 463–8
   PubMed Web of Science ®Google Scholar
• Konrad RJ, Major CD, Wolf BA. Diacylglycerol hydrolysis to arachidonic acid is necessary for insulin secretion from isolated pancreatic islets: sequential actions of diacylglycerol and monoacylglycerol lipases. Biochemistry. 1994; 33: 13284–94
   PubMedGoogle Scholar
• Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001; 410: 822–5
   PubMed Web of Science ®Google Scholar
• Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med. 1985; 26: 125–32
   PubMed Web of Science ®Google Scholar
• Wildburger R, Zarkovic N, Tonkovic G, Skoric T, Frech S, Hartleb M, et al. Post-traumatic hormonal disturbances: prolactin as a link between head injury and enhanced osteogenesis. J Endocrinol Invest. 1998; 21: 78–86
   PubMed Web of Science ®Google Scholar
• Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001; 413: 527–31
   PubMed Web of Science ®Google Scholar
• Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 2008; 20(Suppl 1)69–74
   PubMedGoogle Scholar
• Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 2008; 22: 285–94
   PubMed Web of Science ®Google Scholar
• Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone. 2009; 44: 476–84
   PubMed Web of Science ®Google Scholar
• Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008; 153: 182–8
   PubMed Web of Science ®Google Scholar
• Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001; 98: 3662–5
   PubMed Web of Science ®Google Scholar
• Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A. 2006; 103: 696–701
   PubMed Web of Science ®Google Scholar
• Scutt A, Williamson EM. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int. 2007; 80: 50–9
   PubMed Web of Science ®Google Scholar
• George KL, Saltman LH, Stein GS, Lian JB, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J Cell Physiol. 2008; 214: 714–20
   PubMed Web of Science ®Google Scholar
• Idris AI, Sophocleous A, Landao-Bassonga E, van 't Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology. 2008; 149: 5619–26
   PubMed Web of Science ®Google Scholar
• Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999; 283: 401–4
   PubMed Web of Science ®Google Scholar
• Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Müller R, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol. 2006; 70: 786–92
   PubMed Web of Science ®Google Scholar
• Amor S, Smith PA, Hart B, Baker D. Biozzi mice: of mice and human neurological diseases. J Neuroimmunol. 2005; 165: 1–10
   PubMedGoogle Scholar
• Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999; 96: 5780–5
   PubMed Web of Science ®Google Scholar
• Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984; 1: 1091–3
   PubMed Web of Science ®Google Scholar
• Nogueira-Filho Gda R, Cadide T, Rosa BT, Neiva TG, Tunes R, Peruzzo D, et al. Cannabis sativa smoke inhalation decreases bone filling around titanium implants: a histomorphometric study in rats. Implant Dent. 2008; 17: 461–70
   PubMedGoogle Scholar
• McCaw E, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem. 2004; 271: 4909–20
   PubMedGoogle Scholar
• Zhang P, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry. 2004; 9: 916–31
   PubMed Web of Science ®Google Scholar
• Devoto M, Shimoya K, Caminis J, Ott J, Tenenhouse A, Whyt MP, et al. First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet. 1998; 6: 151–7
   PubMedGoogle Scholar
• Devoto M, Specchia C, Li HH, Caminis J, Tenenhouse A, Rodriguez H, et al. Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet. 2001; 10: 2447–52
   PubMedGoogle Scholar
• Devoto M, Spotila LD, Stabley DL, Wharton GN, Rydbeck H, Korkko J, et al. Univariate and bivariate variance component linkage analysis of a whole-genome scan for loci contributing to bone mineral density. Eur J Hum Genet. 2005; 13: 781–8
   PubMedGoogle Scholar
• Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005; 14: 3389–96
   PubMed Web of Science ®Google Scholar
• Yamada Y, Ando F, Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med. 2007; 19: 791–801
   PubMedGoogle Scholar